IMPORTANCE OF INDIVIDUAL APPROACH TO THE IMMUNOPROPHYLAXIS OF RECURRENT UROGENITAL INFECTION


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Prevention of recurrence of urinary tract infections by Uro-Vaxom is recommended by domestic and international guidelines; up to date, however, there is no reasonable standard regimen for the use of drug, and long-term results of immunoprophylaxis were not evaluated. The study included 48 patients who received a first course of Uro-Vaxom 5 years ago (2007-2008), including 19 men with chronic bacterial prostatitis/urethroprostatitis and 29 women with recurrent cystitis. Over 5 years, 125 recurrences of urogenital infection were observed; Uro-Vaxom along with antibiotics or uroseptics in combination with phytopreparations was used in 88 (70,4%) cases, and in the remaining 37 (29,6%) cases monotherapy with Uro-Vaxom was used for the relief of inflammatory processes. During the follow-up period, 254 1-month courses of treatment with Uro-Vaxom were conducted; 125 (49,2%) courses were assigned for the treatment of recurrent urogenital infection, and 129 (50,8 %) - for the prevention without exacerbation of underlying disease. The main indications for use were intercurrent infection, mainly respiratory - 86 (66,7%) cases, stress - 14 (10,8%); in 29 (22,5%) cases, the patients have received Uro-Vaxom focusing on their feelings without a doctor's prescription.

Texto integral

Acesso é fechado

Bibliografia

  1. Naber K.G., Cho Y.H., Matsumoto T., Schaeffer A.S. Immunoactive prophylaxis of recurrent urinary tract infections: a meta-analysis. Int. J. Antimicrob. Agents 2009; 33(2): 111-119.
  2. Krieger J.N. Urinary tract infections: what’s new? J. Urol. 2002; 168: 2351-2358.
  3. Nicolle L.E. Asymptomatic bacteriuria in the elderly. Infect. Dis. Clin. North Am. 1997; 11: 647-662.
  4. Kun Suk Kim, Ji-Yoon Kim, In Gab Jeong et al. A prospective Multi-center Trial of Escherichia coli extract for the prophylactic treatment of patients with chronically recurrent cystitis. J. Korean Med. Sci. 2010; 25: 435-439.
  5. Huber M., Krauter K., Winkelmann G. et al. Immunostimulation by bacterial components: II. Efficacy studies and meta-analysis of the bacterial extract OM-89. Int. J. Immunopharmacology. 2000; 22: 1103-1111.
  6. Bauer H.W., Rahls W., Lauener P.A., Plessmann G.S. Prevention of recurrent urinary tract infections with immuno-active E.Coli fractions: a meta-analysis of five placebo-controlled double-blind studies. Int. J. Antimicrob. Agents 2002; 19(6): 451-456.
  7. Schulman C.C., Corbusier A., Michiels H. et al. Oral immunotherapy of recurrent urinary tract infections: a double-blind placebocontrolled multicenter study. J Urol 1993; 150: 917-921.
  8. Magasi P., Panovics J., Illes A. et al. Uro-Vaxom and the management of recurrent urinary tract infection in adults: a randomizes multicenter double-blind trial. Eur. Urol. 1994; 26: 137-140.
  9. Hachen H.J. Oral immunotherapy in paraplegic patients with chronic urinary tract infections: a double-blind, placebo-controlled trial. J. Urol. 1990; 143: 759-763.
  10. Tammen H. and the German urinary tract infection study group. Immunobiotherapy with Uro-Vaxom in recurrent urinary tract infection. Br. J Urol. 1990; 65: 6-9.
  11. Schneider H.-J. New therapeutic approach for recurrent urinary tract infections. Marked reduction in recurrence rate in women with uncomplicated cystitis - few side effects, high compliance. Der Allgemeinarzt. 1990; 12: 626-633.
  12. Popa G., Lauber K.-D., Rothe H. et al. Rezidivierende Harnwegsinfektionen in der Postmenopause. Wirksamkeit einer oralen Immuntherapie mit E. Coli-fraktionen. Munch med Wschr 1996; 138: 713-716.
  13. Schmidhammer S., Ramoner R., Holtl L. et al. An Escherichia coli-based oral vaccine against urinary tract infections potently activates human dendritic cells. Urology. 2002 (3); 606: 521-526.
  14. Thilagarajah R., Witherow R.O., Walker M.M. Quantitative hystopathology can aid diagnosis in painful bladder syndrome. J. Clin. Pathol. 1998; 51: 211-214.
  15. Bessler W.G., vor dem Esche U., Zgaga-Griesz A. et al. Immunostimulatory properties of the bacterial extract OM-89 in vitro and in vivo. Arzneimittelforschung. 2010; 60(6): 324—329.
  16. Bauer H.W., Alloussi S., Egger G. et al. A long-term, multicenter, double-blind study of an Escherichia coli extract (OM-89) in female patients with recurrent urinary tract infections. Eur. Urol. 2005; 47(4): 542-548.
  17. Кульчавеня Е.В., Бреусов А.А. Эффективность уро-ваксома при рецидивирующих инфекционно-воспалительных заболеваниях мочеполовой системы. Урология. 2011; 4: 7-11.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies